Remnant cholesterol inflammation index predicts adverse outcomes in patients with acute myocardial infarction: a single-center retrospective study
- 1Department of Cardiology, The First Hospital of Hebei Medical University
- 2Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University
- 3Department of Neurology, The First Hospital of Hebei Medical University
Abstract
Background: Despite treatment, residual cardiovascular and cerebrovascular risk persists post-acute myocardial infarction (AMI). The Remnant Cholesterol Inflammation Index (RCII), combining residual cholesterol and hsCRP, reflects lipid and inflammatory burdens; however, its prognostic value in the acute phase remains unclear. This study evaluated RCII for predicting 30-day major adverse cardiovascular and cerebrovascular events (MACCE).
Methods: A single-centre, retrospective study enrolled 3,280 AMI patients. The primary endpoint was a composite of all-cause mortality, recurrent myocardial infarction and non-fatal stroke within 30 days. Covariates were selected via Boruta and LASSO algorithms. Restricted cubic spline (RCS) and segmented Cox regression analysed the dose-response relationship and threshold effects between lnRCII and outcomes. Subgroup and sensitivity analyses were performed.
Results: lnRCII showed a U-shaped association with 30-day MACCE risk (inflection point: 1.83). Compared to the middle quartile (Q2), patients in Q1, Q3, and Q4 had significantly higher risks (80%, 102%, and 109%, respectively). The association differed by hypertension status ( p for interaction = 0.039), with sensitivity analyses confirming robustness.
Conclusion: This study suggests that RCII may be an independent predictor of 30-day MACCE post-AMI, with both high and low levels correlating with increased risk. These findings should be interpreted as hypothesis-generating. RCII may serve as an integrated biomarker reflecting both lipid and inflammatory burdens for early risk stratification.
Trial registration: The study was approved by the Ethics Committee of the First Hospital of Hebei Medical University (approval no. Y277) and was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. The need for informed consent was waived by the board.
Related
- Role of Inflammation in the Development of Heart Failure After Myocardial Infarction
- Comparative Associations of Inflammation and Nutrition-Based Indices with No-Reflow and Mortality After Primary PCI for ST-Elevation Myocardial Infarction
- Estimated small dense low-density lipoprotein cholesterol and incident myocardial infarction in patients undergoing dialysis: a nationwide cohort study.
- Elevated Lipoprotein(a) Predicts Recurrent Myocardial Infarction in Diabetic Patients Following Acute Coronary Syndromes
- Factors associated with 30-day mortality in patients with post-myocardial infarction ventricular septal rupture: a retrospective cohort study
BibTeX
@article{chen2026remnant,
title = {{Remnant cholesterol inflammation index predicts adverse outcomes in patients with acute myocardial infarction: a single-center retrospective study}},
author = {Xinyue Chen and Yichen Li and Jianwei Ma and Guoyuan Song and Yuanzuo Chai and Chunting Li and Yajuan Yin and Yan Yan and Mingqi Zheng and Fangfang Ma},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = nov,
doi = {10.3389/fcvm.2026.1904167},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1904167/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Remnant cholesterol inflammation index predicts adverse outcomes in patients with acute myocardial infarction: a single-center retrospective study
AU - Xinyue Chen
AU - Yichen Li
AU - Jianwei Ma
AU - Guoyuan Song
AU - Yuanzuo Chai
AU - Chunting Li
AU - Yajuan Yin
AU - Yan Yan
AU - Mingqi Zheng
AU - Fangfang Ma
PY - 2026
DA - 2026/11/04
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1904167
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1904167/full
AB - Background: Despite treatment, residual cardiovascular and cerebrovascular risk persists post-acute myocardial infarction (AMI). The Remnant Cholesterol Inflammation Index (RCII), combining residual cholesterol and hsCRP, reflects lipid and inflammatory burdens; however, its prognostic value in the acute phase remains unclear. This study evaluated RCII for predicting 30-day major adverse cardiovascular and cerebrovascular events (MACCE). Methods: A single-centre, retrospective study enrolled 3,280 AMI patients. The primary endpoint was a composite of all-cause mortality, recurrent myocardial infarction and non-fatal stroke within 30 days. Covariates were selected via Boruta and LASSO algorithms. Restricted cubic spline (RCS) and segmented Cox regression analysed the dose-response relationship and threshold effects between lnRCII and outcomes. Subgroup and sensitivity analyses were performed. Results: lnRCII showed a U-shaped association with 30-day MACCE risk (inflection point: 1.83). Compared to the middle quartile (Q2), patients in Q1, Q3, and Q4 had significantly higher risks (80%, 102%, and 109%, respectively). The association differed by hypertension status ( p for interaction = 0.039), with sensitivity analyses confirming robustness. Conclusion: This study suggests that RCII may be an independent predictor of 30-day MACCE post-AMI, with both high and low levels correlating with increased risk. These findings should be interpreted as hypothesis-generating. RCII may serve as an integrated biomarker reflecting both lipid and inflammatory burdens for early risk stratification. Trial registration: The study was approved by the Ethics Committee of the First Hospital of Hebei Medical University (approval no. Y277) and was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. The need for informed consent was waived by the board.
SN - 2297-055X
ER -